

### Speakers Charité Entrepreneurship Summit 2013

---

#### Co-Chairs

---



#### **E. Jürgen Zöllner**

E. Jürgen Zöllner has been Executive Director of Stiftung Charité since May 2012. Before that, he served as Senator for Education, Youth and Science in Berlin (2006-11) and as Minister for Education, Science, Further Education and Culture in Rhineland-Palatinate (1991-2006). Previous to his political career E. Jürgen Zöllner was President of Johannes Gutenberg University Mainz. He studied medicine at the University of Freiburg and Johannes Gutenberg University Mainz and was a full professor at the latter institution for many years.



#### **Karl Max Einhäupl**

Prof. Dr. Karl Max Einhäupl is Chairman of the Executive Board of the Charité – Universitätsmedizin Berlin and has served in this position since 2008. He is one of the most distinguished neurologists in Germany and from 2001-2006 served as the President of the Scientific Advisory Council to the German Federal Government (Wissenschaftsrat). During his scientific career he has received numerous awards and is a member of the Leopoldina, the National Academy of Sciences in Germany. Since 2013 Prof. Einhäupl has been a Member of the Board of Directors of the Berlin Institute of Health (BIH).



#### **Walter Rosenthal**

Walter Rosenthal was appointed Scientific Director of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch in January 2009. The institute belongs to the Helmholtz Association of National Research Centers. Walter Rosenthal studied medicine at the Justus-Liebig-Universität Gießen, Germany, and at the Royal Free Hospital, School of Medicine in London, United Kingdom. In 1990, he became Assistant Professor (Habilitation) at the Free University of Berlin, Germany, carrying out studies on G-proteins, followed by two years as Visiting Professor and Heisenberg Fellow at Baylor College of Medicine, Houston, Texas, USA. From 1993 – 1996, he was the Director of the Rudolf-Buchheim-Institut for Pharmacology at the University of Gießen. In 1996, he became the Director of the Leibniz-Institut für Molekulare Pharmakologie (FMP) and, in 2000, was responsible for moving the FMP to the Berlin-Buch Campus in order to work more closely with the MDC. He is also a professor at the Charité – Universitätsmedizin Berlin, one of the largest university hospitals in Germany.

#### Dinner Speaker

---



#### **Georg Schütte**

Dr. Georg Schütte has been serving as State Secretary at the Federal Ministry of Education and Research since 2009. Prior to his current position he was Secretary General of the Alexander von Humboldt Foundation in Bonn (2004-09), Executive

Director of the German-American Fulbright Commission in Berlin (2011-03), and he served as member of the expert group "Benchmarking Human Resources" for the European Commission in Brussels (2001-02). Dr. Schütte studied journalism and was trained at the City University of New York, Harvard University, and Dortmund University, where he received his PhD in 1994.

---

### Confirmed Speakers

---



#### **Reinhard J. Ambros**

Dr. Reinhard J. Ambros is Global Head of Novartis Venture Funds. Located in Basel, Switzerland. Previously, he was Managing Director of the Novartis BioVenture Fund in the USA. He also worked with Novartis Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post merger integrations at Novartis Corporate M&A and was global head BD&L cardiovascular and metabolic diseases at Novartis Pharma. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche. He trained as a pharmacist, has a PhD in medicinal chemistry and pharmacology and focused postdoctoral training in clinical pharmacology. Board seats include Cylene, Forma, Genedata, Symetis and Tokai.

---



#### **Ida Beerhalter**

Ida Beerhalter is Co-Head of IOME, a private investment office based in Riyadh, KSA. Additionally she currently serves as member of the Board of Trustees of Astia, San Francisco, USA, a unique not-for-profit organization built on a community of over 3000 experts dedicated to propel women's full participation as entrepreneurs and leaders in high-growth businesses, fueling innovation and driving economic growth, as Investment Advisor at Bellwald Partner GmbH, Moehlin, Switzerland, the investment arm of a multi family office, as Strategic Advisor to Impact Investment Partners LLP, London, specialized in investing in critical service sectors in emerging markets, as Advisor to Yunus Social Business GmbH, Germany, dedicated to setting up and investing in non-dividend companies created to solve sustainably social or environmental problems, as Advisor to CR Global, Washington DC, a worldwide strategic 360° liaison agency for companies and investors, as Consultant to Shanghai Biomedical Enterprise LLC, Hong Kong, as Director Corporate Affairs at Cardionovum GmbH, Germany, a specialized in Drug-Eluting technologies and biodegradable vascular scaffolds and as Advisor at MedPrivee, which she co-founded in 2011. Ida is registered acquisition coach at High-Tech-Gründer-Fonds, Germany, which is managing two +250 mio € seed funds in Germany and which has helped to start up more than 270 companies since 2005, and serves as juror and coach at the European Venture contest, which identifies each year the most promising European companies from the LifeSciences, ITC and CleanTech sector out of more than 700 companies. Prior to her current roles she served as Investment Partner at Bellwald Partner GmbH, as Head of Business Development at NonWoTecc Medical GmbH, as Vice President, Business Development at mNEMOSCIENCE GmbH, and as Director Business Development, Sales Manager and, Training and Education Manager at the KRAUTH group. Before joining the KRAUTH group, Ida served as European Marketing Manager at Medtronic Inc., and as Marketing Manager at both AVE GmbH and Cordis GmbH, the latter of which is where she started her career as Sales Area Manager in 1992.

---



### **Ralf Belusa**

Dr. Ralf Belusa studied Micro- and Nanotechnology at the University Munich, and was the first student at the LMU Ludwig-Maximilians-University Munich, who awarded a special doctoral accreditation in Humanbiology/Neurology (Prof. Dr. med. Dr. h.c. Thomas Brandt, FRCP). Furthermore he finished his Masterstudies as a Master of Science in Systems Engineering (MSE) with his Thesis on Pharmacoepidemiology at the LMU and the Harvard Medical School and has earned his doctorate degree at the Humboldt-University of Berlin / Clinic of General-, Visceral-and Transplantation Surgery of the Charité.

---



### **Mark Brincat**

Mark Brincat leads the strategy and development of Exco InTouch's range of patient-centric services and mHealth solutions, with particular focus on the advancement of engagement solutions targeted to specific therapy areas that can be pre-configured to the challenges of a particular disease and patient population.

Prior to joining Exco InTouch, Mark spent the last thirteen years at Pfizer managing the delivery of emerging and innovative business technology. Recognized as one of Pfizer's leading innovators, he most recently led its Healthcare Informatics division in Europe, during which time he developed pioneering solutions across clinical trials, drug compliance, disease management and wellness.

Mark has a background in software engineering for a number of blue chip organizations across multiple industries, throughout which the delivery of innovative technology solutions has been a key theme.

---



### **Charles Cameron**

Charlie Cameron has over 20 years of management consulting, business development and investing experience in more than 20 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies and has been a judge for business plan competitions. He founded the Hub Angel Investment Group in 2001, which is now on its 4th fund. Hub's biggest exit was Zipcar, a car-sharing firm, which had an IPO. He works with entrepreneurs and innovators in Berlin and other cities in Germany, with special focus on developing pools of investment capital. Charlie is also Senior VP of Business Development at Cooley LLP, which is a national law firm in the US, with deep experience working with life science and tech companies and venture funds. During the past decade Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics- honors, Phi Beta Kappa, from the University of Massachusetts.

---



### **Christopher M. Coburn**

Chris Coburn has served as Executive Director of Cleveland Clinic Innovations (CCI), Cleveland Clinic's corporate venturing arm, since it was established in May 2000. He has built a high performing team of more than 65 professionals. Cleveland Clinic's 55 spin-off companies have raised nearly USD 700 million in equity investment – before Coburn's arrival the Clinic had no technology spin-offs. In June 2012, Innovations was recognized by Global Corporate Venturing as one of the world's top four healthcare corporate venturing organizations. Mr. Coburn serves on the board of directors of Autonomic Technologies, Explorys, i360 Medical, and BioEnterprise. He is a former Vice President and General Manager of Battelle Memorial Institute and director of the U.S. Enrichment Corporation (NYSE:USU). He wrote and edited the only comprehensive profile of public

sector commercialization initiatives, has published numerous articles, and has collaborated on other publications. He has consulted, testified and spoken on technology commercialization throughout North America and in more than two dozen countries. He is a member of the IBM's Watson Advisory Board, Ohio's 3rd Frontier Advisory Board, a trustee of Cuyahoga Arts and Culture and the City Club of Cleveland. In 2012 he was selected as one of the 100 top corporate venture professionals in the world. He and his wife, Nancy, live in Shaker Heights and have three grown children.



### **Jean-Jacques Degroof**

Jean-Jacques Degroof has been an active business angel both in Boston and in Europe since the year 2000, including in the biomedical sector. While in Boston, he also worked at the MIT Industrial Performance Center where he collaborated to research on the role of universities on local economic development, as well as on comparing innovation systems in the USA and the UK. Jean-Jacques also investigated universities spin-off ventures in regions with weak entrepreneurial environment. Over the years, he has consulted with governments and government agencies on these issues. Jean-Jacques holds a Master of Science and a Ph.D. in Management from the MIT Sloan School of Management.



### **Klaus-Peter Döpfer**

Klaus-Peter Döpfer, PhD has been serving as Director in Polymer Chemistry at the European Patent Office, Munich, Germany, since 2007. Prior to that, he served as Chairman of the Examining and Opposition Divisions and as Deputy Director in Biotechnology (2003-06). Before that, he was an examiner for the technical fields diagnostics, proteins/peptides in The Hague, Netherlands and Munich. Klaus-Peter Döpfer studied chemistry and biochemistry and holds a diploma and a doctoral degree in bioinorganic chemistry. He worked as a scientist and research group leader in different research labs (chemistry, biotechnology, toxicology) for several years before he joined the European Patent Office. During the last 20 years he has held numerous presentations and seminars on IP matters worldwide.



### **Horst Domdey**

Horst Domdey, a trained biochemist, held research positions in Germany, Switzerland and the United States, before he became Professor for Biochemistry at the University of Munich in 1994. In the same year he co-founded MediGene, one of the first biotech companies in Germany. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he has been the Managing Director of Bio<sup>M</sup>, the cluster development and management organization of the Munich Biotech Cluster. Since 2006 he also manages the Bavarian Biotechnology Cluster. Since 2003, he is the scientific director of the Bavarian Genome Network BayGene, since 2011 the coordinator of the Bavarian Center for Molecular Biosystems BioSysNet. Horst Domdey is cofounder of BIO Deutschland, of the Association of the German BioRegions and of the Council of the European BioRegions (CEBR). In 2010 the Munich Biotech Cluster became – under his leadership – one of the winners in the German Leading Edge Cluster Competition.



### **Lauren C. Foster**

Lauren C. Foster is the Assistant Director of M.I.T.'s Technology Licensing Office (TLO), focusing principally on licensing and commercialization of technologies in the biomedical, biotechnology and medical device fields. She also serves as Director of Intellectual Property and Strategic Alliances at the Koch Institute for Integrative Cancer Research at M.I.T. where she is involved in the strategic management of the Koch Institute's industrial partnerships and intellectual property portfolio. Prior to joining M.I.T., Lauren was Senior

Director, IP and Technology Acquisition at Antigenics, Inc., a public biotechnology company, where she played an integral role in envisioning and implementing the company's business, intellectual property and technology strategies. Lauren was also a Technical Specialist at the law firm Lahive & Cockfield LLP where she focused on strategic development of intellectual property rights for biotechnology and pharmaceutical companies and universities. Ms. Foster holds a D.Sc. from Harvard University and a B.S. from Haverford College, and is a registered Patent Agent.

---



### Alexander von Frankenberg

Dr. Alex von Frankenberg is Managing Director of the High-Tech Gründerfonds. Before taking that position in October 2005 he was responsible for spin-offs as Venture Manager at the Siemens Technology Accelerator (STA). Before joining the STA in April 2002 Alex was head of sales and marketing of an IT start-up. Prior to that he headed the Innovation Practice at Siemens Management Consulting. He started his career designing and implementing large IT systems with Andersen Consulting. Alex holds an MBA from the University of Texas at Austin (1992) and a PhD from the University of Mannheim (1997).

---



### Giovanni Frisoni

Giovanni Frisoni is a clinical neurologist, Deputy Scientific Director of the National Alzheimer's Center in Brescia, Italy as well as Head of the local Laboratory of Neuroimaging and the Translational Care Unit. He is author of over 350 scientific papers listed in PubMed, imaging editor for *Neurobiology of Aging*, and founding editorial board member of *The Lancet Neurology*. He serves as Principal Investigator of European Commission funded projects FP6 *ENIR* (2006-07), FP7 *neuGRID* (2008-10), FP7 *outGRID* (2009-12), and FP7 *neuGRID for users* (2011-14), aiming to develop an innovative work environment for imaging neuroscientists based on cloud computing. He has brought ADNI to Europe with the Alzheimer's Association's grant *Pilot European ADNI* (2005-06) and IMI Pharmacog WP5/EADNI (since 2010). Also, he was able to bring ADNI and DIAN to Italy with the Italian ADNI (2010-12) and Italian DIAN (since 2012), funded by the Italian Ministry of Health. Giovanni Frisoni leads the project *Harmonized Protocol for Hippocampal Volumetry* (2010-ongoing), funded by the international Alzheimer's Association. The aim of the project is to standardize the manual segmentation of the hippocampus globally. He served as chairman of the Alzheimer's Imaging Consortium at ICAD in 2010 and 2011. In addition, he has brought amyloid imaging to Italy with the ISS "Relationship between 18-flutemetamol Amyloid imaging and post-surgery delirium in elderly".

---



### Steven Gullans

Steve is an experienced investor, entrepreneur, writer, and scientist. At Excel, he focuses on life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. He is a board director at Activate Networks, Tetrphase Pharmaceuticals, PathoGenetix, nanoMR, Cleveland HeartLab, and Catch.com and previously at BioTrove, Biocius, and RxGen, where he was co-founder and CEO. Steve was a faculty member at Harvard Medical School and Brigham and Women's Hospital for nearly 20 years. He has published more than 130 scientific papers in many leading journals, lectured internationally, and co-authored numerous patents. He and Juan Enriquez recently co-authored *Homo evolutis: A Short Tour of Our New Species*, which describes the future of human evolution, as well as a recent commentary in *Nature* entitled *Genetically Enhance Olympics are Coming*.

---





### **Eric Halioua**

Eric Halioua is the CEO of the Belgian Biotechnology company Promethera Biosciences. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using stem cell from healthy human livers. He is as well Board members of the European Biopharmaceutical Enterprises (EBE) and of the Belgian Walloon region Biocluster (BioWin). Eric is co-founder of two biotechnology companies called Myosix and Murigenetics. Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been sold to Genzyme mid-2002. Murigenetics is a Biotechnology company developing therapies for genetic disorders. Eric was also a Board Member of a French public biotechnology company called Vivalis, which specializes in the production of avian stem cells lines for the production of vaccines and recombinant proteins. Eric was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, M&A and technology & innovation management for biotechnology and pharmaceutical companies. Eric also worked as a strategic marketing manager for the "Centre Européen de Bioprospective" and as project leader in the corporate R&D centre of Zeneca in UK. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

---



### **Samir Hanash**

Dr. Hanash is a Full Member at the MD Anderson Cancer Center and Director, McCombs Institute for Cancer Early Detection and Treatment. Dr. Hanash's interests and expertise focus on the development and application of integrated approaches to the molecular profiling of cancer, with particular emphasis on the application of proteomics to the development of blood based cancer biomarkers. He has been a program principal investigator for several multi-investigator projects aimed at biomarker discovery and validation. He is the inaugural president of the Human Proteome Organization.

---



### **Charles Harding**

Dr Charles Harding is a partner and European patent attorney at D Young & Co LLP, a leading intellectual property law firm. Charles represents academic organisations, SMEs and blue chip companies before the UK Intellectual Property Office and the European Patent Office in patent matters in the life sciences sector. His portfolio covers various technologies such as molecular biology, immunology, biotechnology, virology, veterinary science, food science, protein chemistry, chemistry, pharmacology, pharmaceuticals and devices. Charles has chaired and/or lectured at numerous international conferences and conventions on life science issues in the patent arena and is able to provide a highly experienced and strategic view on the commercialisation of technology, from initial evaluation and protection, to the identification of market need and of valuable end users and possible partners.

---



### **Dietmar Harhoff**

Prof. Dietmar Harhoff Ph.D. is Director at the Munich Center for Innovation and Entrepreneurship Research (MCIER) at the Munich-Max-Planck Campus for Legal and Economic Research. At the Ludwig-Maximilian-University Munich he is Honorary Professor of Business Administration. He is the Chairman of the Expert Commission on Research and Innovation (EFI) which advises the German government on its innovation policies. He is also a member of the Economic Advisory Group of the European Commission and of an advisory group at the European Patent Office.



### **John Harthorne**

John Harthorne is the Founder and CEO of MassChallenge, the largest-ever startup accelerator and competition. Startups participating in the 2010 and 2011 MassChallenge accelerator have raised over 0M and created over 2,000 jobs. The 2012 MassChallenge competition received over 1,230 applications from 36 US states and 35 countries. In January of 2011, President Barack Obama identified MassChallenge as one of America's most effective startup accelerators. John received his MBA from the MIT Sloan School of Management in 2007. While at school, John received Grand Prize in the 2007 MIT 0K Business Plan Competition and received the 2007 Patrick J. McGovern Award for impact on quality and visibility of entrepreneurship at MIT. He also led the 10th annual MIT Global Startup Workshop (GSW) held in Trondheim, Norway. In September 2011, the Boston Business Journal identified John as one of Boston's 50 Most Influential Business Leaders, alongside the CEOs of Akamai Technologies, Blue Cross Blue Shield and the Boston Celtics. John is a life-long Massachusetts resident and an avid Red Sox fan. He currently lives in Somerville with his wife Natalia, their 6-year old son Max and their 2-year old girl Yulia.

---



### **John Hession**

John Hession is a partner in the Venture Capital Financings and Emerging Companies practice groups and a member of Cooley's Business department. Cooley is a nationally recognized leader in financings, strategic alliances, acquisitions and public offerings of life science, medical device and technology companies. John helped found Cooley's Boston office in 2007 and was also former Managing Partner of the Boston office. After three years under John's tenure, Cooley's Boston office was ranked by U.S. News & World Reports as one of the "Top 3 Firms in Boston for venture capital and technology law." John represents emerging-growth companies, principally in the medical device, life sciences, software, telecommunications and electronic commerce fields, as well as angels and venture capital funds in the investment process in these sectors. During his thirty-year career, John has participated in, structured and negotiated more than 300 venture and angel financings, 30 public offerings, more than 350 strategic alliances involving technology licenses, transfers and joint ventures, and 200+ acquisitions ranging in size from \$1.0 million to \$4.2 billion. John received his law degree, *cum laude*, from Boston College Law School, and graduated with his B.A., English, *summa cum laude* and as a member of Phi Beta Kappa, from The University of Notre Dame.

---



### **Barbara Keck**

Barbara Keck, PhD is CEO of BAGSO Service GmbH (Bundesarbeitsgemeinschaft der Senioren-Organisationen), funded by the Federal Ministry of Family, Senior Citizens, Women and Youth. Before she joined BAGSO in 1999 she held several positions as researcher at the University of Bonn, the University of Koblenz-Landau, the University of Cologne, and the German Sport University Cologne (1987-98). Barbara Keck studied Psychology at the University of Bonn, where she also received a doctoral degree.

---



### **Stefan Koelsch**

Stefan Koelsch has been a full professor for Biological Psychology and Music Psychology, Dept. of Education and Psychology, Freie Universität Berlin, Germany since 2010. He is a member of the Cluster of Excellence "Languages of Emotion" at Freie Universität Berlin. Prior to that, he held a RCUK fellowship (senior researcher) at the University of Sussex (2006-10). Before that, he held positions at the University of Leipzig and the Max Planck

Institute for Human Cognitive Science in Leipzig, Germany where he received his doctoral degree in Psychology ("Brain and Music: A contribution to the investigation of central auditory processing with a new electrophysiological approach"; summa cum laude) in 2000. From 2001 through 2002 he was a Postdoctoral fellow at Harvard Medical School (Gottfried Schlaug's Lab.), Boston, USA.



### **Heike von Lützu-Hohlbein**

Born 1946, educated as computer scientist, graduated by the Technical University of Munich, worked the last years of her career as executive director of her own software company, now retired. More than 20 years ago she became involved in the German Alzheimer movement because of her mother living with Alzheimer's and later her mother-in-law. Since 2001 she is president of the Deutsche Alzheimer Gesellschaft, the umbrella organisation of the German Alzheimer and dementia self help groups. Since 2010 she is also chairperson of Alzheimer Europe, the European umbrella association of the national Alzheimer organisations. In her function she is involved in the development of plans for better care for people with dementia. In numerous publications and presentations she is an advocate of the people with dementia and their carers. She was decorated with the Cross of the Order of Merit of the Federal Republic of Germany in 2009 because of her honorary work for the people with dementia and their families.



### **Maria Ly**

Maria is a health and fitness fanatic. Her interest in wellness and mobile technology inspired her to create Skimble. She is a Rock Health Fellow and has spoken about the mHealth revolution at TEDxUW, Mobile Health at Stanford, and the Health Innovation Summit in San Francisco. Prior to Skimble, Maria spent time in international product and marketing roles at Google, Flurry and Cypress. She graduated from the University of Waterloo with a BAsci in Computer Engineering and minored in Management Sciences and International Studies in Engineering. Maria has also represented Canada at the World Cheerleading and Dance Championships. Skimble powers the mobile wellness movement with fun, dynamic & social coaching applications for everyone. With over 10 million downloads, Skimble's apps foster a supportive and engaged community that reaps the rewards of living an active lifestyle. Skimble collaborates with leading health professionals including a partnership with the Harvard Medical School. Additionally, Skimble is a graduate of the Rock Health accelerator program.



### **Andreas Manz**

Andreas Manz is a full professor at the Department of Mechatronics at Saarland University in Saarbrücken, Germany. In addition, he has been serving as Head of Research at the Korea Institute of Science and Technology (KIST) in Saarbrücken since 2010. Before that, he was Head of the Institute for Analytical Sciences (ISAS) in Dortmund and Berlin, Germany. From 1995 through 2004 Andreas Manz was SmithKline Beecham Professor of Analytical Chemistry at Imperial College, Dept. Chemistry, London, UK. Prof. Manz received his PhD from the Swiss Federal Institute of Technology Zurich (ETH), Switzerland in 1986. Afterwards he was a postdoctoral fellow at Hitachi Central Research Lab., Hitachi Ltd., Tokyo, Japan (1987-88) and worked as researcher and later as group leader at Ciba-Geigy Central Research Lab., Basel, Switzerland (1988-95). In 1995 Prof. Manz's habilitation thesis on 'Micro System Technology for Use in Analytical Chemistry' was accepted at the Technical University (TU) Vienna, Austria. Following this he served as scientific advisor and consultant of Caliper Technologies, Mountain View, California until 2000. The company is active in "lab on chip" technology. From 1994 through 2008 he was a member of the scientific committee and the board of  $\mu$ TAS, the International Symposium on Micro Total Analysis Systems. He is a member of the permanent scientific committee of MSB (previously HPCE), the International Symposium on Microscale



Separations and Analysis since 2000. From 2001-08 he served as journal founding member and chairman of the editorial board of 'Lab on a Chip' (Royal Society of Chemistry, UK).

---



### **Ljubisav Matejevic**

Ljubisav spent the last 7 years working as an Alliance Executive for Global Healthcare in IBM where he collaborated with federal, provincial and territorial governments, as well as private healthcare providers and insurers to facilitate the delivery of better healthcare. Before this, Ljubisav worked as IBM's Principal Public Sector Adviser in Central and Eastern Europe, Russia, Middle East, and Africa. He is the Founder and Honorary Chairman of the Global E-Health Forum, as well as a contributor to several healthcare organizations. Ljubisav has run sessions with public authorities across Europe. He is often invited to provide expert commentary on developments in health and has spoken at many conferences. He is Global Market Development Executive at IBM/ Curam for Health and Social Care Coordination.

---



### **Yaacov Michlin**

Yaacov Michlin joined Yissum in 2009 and serves as Yissum's President and Chief Executive Officer. Mr. Michlin has been leading and assisting pharmaceutical, hi-tech and biomedical companies (including Teva, Bioline, CBI and Brainsway) in various technology commercialization deals, licensing agreements, capital raising, mergers and acquisitions and joint venture collaborations. Mr. Michlin was involved in the foundation and strategic guidance of a few companies and ventures. Prior to joining Yissum Mr. Michlin was a partner at Tulchinsky Stern & Co. Law Offices. He holds a Bachelor of Law and Economics, cum laude, and a Master of Law degree, both from Bar-Ilan University, Israel, and an MBA, cum laude, from the Technion Israel Institute of Technology, Israel.

---



### **Marc Molitor**

Marc Molitor is the Managing Director of CAPITAL4IP, an independent, Luxembourg based, investment company. His focus is on helping companies leverage their Intellectual Property to finance their growth and development. M. Molitor serves as an advisor to Burrill & Company, a diversified global financial services firm focused on the life sciences industry with .5 billion in assets under management; the firm's businesses include venture capital/private equity, merchant banking, and media. Mr. Molitor passion and experience is to help build and grow companies, creating new business and market segments. As such he is the co-Founder of the THE GREENHOUSE, a Luxembourg-based accelerator nurturing start-ups in the areas of ICT, Mobile, Social Media, Gaming and Digital Healthcare and also serves as board member of LBAN (Luxembourg Business Angel Network). Mr Molitor started his career in Healthcare at Johnson & Johnson, where he spent 9 years at various leadership positions in the medical device sector, before following his entrepreneurial passion by joining a start-up in the area of telemedicine. In 2010 he became the CEO of MONITOR-it, a start-up combining new ways of healthcare delivery (remote patient monitoring) with thorough clinical strategies to develop a novel indicator for early detection of acute heart failure events (3<sup>rd</sup> place at the Charité Entrepreneurship Summit 2011). Mr. Molitor holds a Master Degree in Engineering from the Swiss Federal Institute of Technology (ETH) in Zurich, as well as an MBA from INSEAD in Fontainebleau (France).

---



### **Bernd Monitor**

Bernd Monitor is Chairman of Business Angels Club Berlin e.V. since 2008. He founded mms AG in 1987, was CEO for many years, and served as member of the Board of Directors until 2011. He was born in Neuss, Rhineland, in 1962.

---



### **Markus Müschenich**

Markus Müschenich is the founder of ConceptHealth, a think tank with longterm expertise in strategic business development based on health care's future foresight analysis. Dr. Müschenich is a board certified pediatrician and has a degree in Public Health. After more than ten years membership of executive boards in private and nonprofit hospital companies, he co-founded Ventures4Health, a German company builder and accelerator for health startups. Ventures4Health partners with founders, connects geeks and healthcare professionals and supports market access of innovative products and services.

---



### **Nina Nashif**

Nina Nashif is Founder and CEO of Healthbox, a business platform created to stimulate global innovation and entrepreneurship in the healthcare industry. Healthbox is one of the first business accelerator programs to focus exclusively on the healthcare industry. Nina is best known for her expertise in creating entrepreneurial ventures and leading high performing teams to achieve results. Her background includes more than ten years of global business experience within very different organizational settings. Prior to joining Sandbox, she was on the executive leadership team of Sg2, a private healthcare analytics and consulting firm, where she founded and led the international division based in London, England. While at Sg2, she worked with both the public and private healthcare sectors in more than ten countries around the world, including the United Kingdom, United Arab Emirates, Thailand, Singapore, Hong Kong and Australia. Her professional experience also includes tenure as Consultant to the leadership team of the Health Authority Abu Dhabi, Director of Market Development in the International Services Division of The Methodist Hospital in Houston, Texas and Cofounder of a Turkish cotton textile business in New York/Istanbul. Nina received her undergraduate degree from the University of Illinois at Urbana-- Champaign and her Master of Science in Health Administration from Washington University School of Medicine in St. Louis, Missouri. Nina is a well-known thought leader that is very passionate about stimulating innovation in the healthcare industry and supporting entrepreneurship across sectors. She is a frequent speaker on these topics at conferences and events around the world. She is also a member of the International Women's Forum, the Life Sciences Advisory Board of Springboard and the Executive Council of Women in Healthcare & Life Sciences. In 2012, Nina was named "Top 40 Under 40" and "Tech Top 50" by Crain's Chicago Business.

---



### **Alexander Olek**

Alexander Olek, a serial entrepreneur, has set up several successful companies in biotechnology, Internet and services. In 1998 he founded Epigenomics and served as its CEO for eight years. Under his leadership this bio- technology company, which launched a groundbreaking test for the early detection of cancer, went public in 2004. One year later, he founded PHORMS, a private school network in Germany with an innovative educational concept. At the end of 2009, he left PHORMS to set up Nobel Education Network.

---



### **Laura Paglione**

Laura Paglione is an entrepreneurial, technically versatile, resourceful leader who thrives at the intersection of creative, technical and business environments. She currently serves as Technical Director of ORCID, where she is directing the technical efforts in ORCID's mission to address name ambiguity for researchers, and serve as a gateway to connect their research activities from disparate sources. Previously as Director, Advancing Innovation at the Kauffman Foundation, Laura directed the efforts of the iBridge Network, an innovation catalyst for university collaboration and technology commercialization. In prior positions at Ford Motor Company and Avid Technology, as well as several start-up/gazelle companies, Laura has turned around, launched and led 4 other high-profile initiatives, the most visible of which was for Ford Motor Company's Board of Directors. Laura earned her Master of Business Administration from the MIT Sloan School of Management, her Master of Science degree in Computer Science from Brown University, and her Bachelor of Engineering from Stevens Institute of Technology.



### **Oliver Peters**

Oliver Peters has been serving as Head of the Department „Old Age Psychiatry“ at Charité – Universitätsmedizin Berlin since 2008. In addition he works as assistant medical doctor and attending psychiatrist at Charité Campus Benjamin Franklin. He received his training at the Charité, and spent several years as a postdoctoral fellow at Heinrich-Heine-University Düsseldorf and the Max Delbrück Center for Molecular Medicine.



### **Josef Priller**

Josef Priller is a full professor and Director as well as Vice Chair of the Department of Psychiatry and Psychotherapy at the Charité. His main research foci are Mechanisms of Inflammation and Neurodegeneration in the CNS, Regenerative Medicine, Stem Cells, Neuropsychiatric Disorders, and Neuroprotection. He serves on the Editorial Boards of several journals (Glia, PLoS ONE, Brain Pathology) and is inter alia a member of the Berlin-Brandenburg Academy of Sciences and Leopoldina. Josef Priller studied Medicine at the University of Bochum, Technical University Munich, Université de Lausanne, Georgetown University and Harvard University.



### **Joachim Rautter**

Joachim is a co-founder of Peppermint VenturePartners and one of the managing partners in the Charité Biomedical Fund. Prior to the launch of Peppermint VenturePartners he was Investment Director at Peppermint Holding GmbH in Berlin, where he was responsible for the investment activities of the Peppermint Industry Group and the establishment of its first Venture Capital fund in 2000. Joachim has more than 12 years of experience in Venture Capital. He is currently holding board seats of CEVEC Pharmaceuticals, CryoTherapeutics and Innolume.



### **Yashu Reddy**

Yashu is a Director for the Healthbox Europe programme and was a founding member of the team that launched the first Healthbox programme in Chicago. Yashu has an international business development and account management background. Prior to joining Healthbox, she was Manager of International Business Development for Sg2, a private healthcare analytics and consulting firm based in London. Yashu worked with healthcare providers and industry clients in the United Kingdom, Europe, Southeast Asia, Middle East and Australia. Her background also includes experience teaching English in

Tokyo. Yashu has a Bachelor of Arts in Psychology and a Minor in Business Administration from The University of Texas at Austin.

---



### **Clemens A. Schmitt**

Prof. Dr. med. Clemens A. Schmitt is a full professor at Charité - Universitätsmedizin Berlin and executive clinical consultant at the Department of Hematology, Oncology and Tumor Immunology (Director: Prof. Dr. med. Bernd Dörken), Charité as well as a guest group leader at the Max-Delbrück-Center for Molecular Medicine in Berlin-Buch. He is Director of the Molecular Cancer Research Center (MKFZ) of the Charité since 2006. In addition, he is founding Director of the Berlin School of Integrative Oncology (BSIO), which is funded by the Excellence Initiative of the German federal and state governments. Before joining the Charité faculty, Clemens Schmitt held a post graduate research fellowship at the Cold Spring Harbor Laboratory, New York, USA. His main research interests are cellular stress responses - apoptosis, senescence and autophagy - in tumor development and treatment resistance (with particular emphasis on malignant lymphoma and other hematological malignancies). He is speaker/coordinator of several research groups and networks funded by the German Research Foundation (DFG) and other grant agencies. He received numerous scientific awards in the area of cancer research, among them the Artur Pappeheim Award by the German Society of Hematology and Oncology and the Curt-Meyer-Memorial Award by the Berlin Cancer Society. His works were published in international top-ranked journals such as Nature and Cell.

---



### **Johannes Schneider-Littfeld**

Johannes Schneider-Littfeld earned a BSc, MSc in Biomedical Engineering and has been working in biomedical research in endocrinology for several years. He then started his industry career at the international consulting firm Sudler&Hennessey Healthcare followed by leading positions as managing director/CEO at Disetronic, Becton-Dickinson and Bauerfeind. He successfully started businesses in new territories like Eastern Europe and Asia as well as brought new technologies from development to market. At Otto Bock Healthcare he is leading M&A and Business Development. He is Board Member of various international Healthcare companies.

---



### **Axel Sigmund**

Since 2008 working for VDI/VDE Innovation + Technik GmbH in the field of Research Funding, Technology Policy and Innovation Management. Axel Sigmund is a Consultant and Project officer for information and communication and assistive technologie projects in the field of Human-Technology-Interaction and Demogrphic Change. He is also involved in the evaluation and development of technology projects and networks. He is the National Contact Point for Human-Technology-Interaction in Demographic change and the AAL Joint Programme He studied medical engineering science and worked more than ten years as an orthopaedic technician.

---



### **Bernd Sommer**

Bernd Sommer received his PhD in 1988 with the University of Bonn. Bernd did his postdoctoral training at the Center for Molecular Biology in Heidelberg between 1988 and 1992 where he participated in the first cloning and characterization of ionotropic glutamate receptors. He joined Sandoz Pharma as a laboratory head in 1992. His laboratory was instrumental in generating one of the first transgenic mouse models for Alzheimer's disease. Between 1995 and 2002 Bernd directed research activities on neurodegenerative diseases at Novartis/Sandoz in Basel, Switzerland. Bernd joined Boehringer Ingelheim in Biberach, Germany in 2002. He has been responsible for several

key areas and today heads the discovery of new therapies in the fields of CNS Diseases. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.



### **Elisabeth Steinhagen-Thiessen**

Prof. Elisabeth Steinhagen-Thiessen has been Chief Consultant and Director of the Protestant Geriatric Centre of Berlin since 1995, a cooperation between the Humboldt-University of Berlin and the Virchow hospital. Upon completing her studies in physics, chemistry and medicine she worked as an assistant doctor at several clinical institutes in Germany. After finishing her doctorate, Dr. Steinhagen-Thiessen worked at the department of biology at Haifa University (Israel) where she was active in the research project "biology of ageing". Upon returning to Germany, she worked at the hospital in Hamburg, where she completed her habilitation (university lecturing qualification) in 1985. Since then, Prof. Steinhagen-Thiessen has lectured at universities in Hamburg, Kassel and Berlin. In 1987, she was elected president of the international congress "Biomedical Gerontology" and was also the Chief Consultant at the "Albertinenhouse", a clinic for gerontology and rehabilitation in Hamburg. From 1987 to 1996 she held a C3-lectureship at the Virchow hospital in Berlin. During this time, Prof. Steinhagen-Thiessen was also the Chief Consultant of the Department of Gerontology at the Max-Bürger-Hospital in Berlin. In 1997 she received a C4-lectureship in internal medicine/gerontology at the Charité in Berlin. Prof. Steinhagen-Thiessen has received several awards for her scientific research. Her dedication and ambition in and for gerontology is evidenced by her numerous memberships and activities in national and international gerontology organisations. Also active in publishing specialised literature, Prof. Steinhagen-Thiessen is the Director of the Federal Association of Geriatric Organisations in Germany.



### **Sebastian Surma**

Sebastian Surma is an Investment Manager at Fraunhofer Venture, which is the central management department for high-tech start-ups and investments of Fraunhofer in Munich. In this role he advises, supports and manages new spin-off companies on their way out of Fraunhofer's research laboratory's and on to a commercially successful application on the market. The focus of the portfolio he supervises is based on the topics of the Fraunhofer ICT research alliance, a group of 18 IT-related research institutes. In addition to his duties in managing his portfolio, he also focuses on the development of new concepts for improving the support for research based high-tech spin-off companies. Before joining Fraunhofer Venture, Sebastian worked as a business analyst at the BMW Group in Munich, where he was part of a team that concentrated on the development and optimization of the sales and customer service processes of the BMW Bank. He gained additional corporate experience at his former position at IBM. Sebastian studied at the University of Cologne, where he earned a degree in business administration and computer science. During that time he was also engaged as the founder of the internet startup NetBabylon, a specialist for the development of online games, designed to support the viral marketing campaigns of Netbabylon's customers.



### **Franz Theuring**

Franz Theuring is Professor of Molecular Pharmacology at the Charité - Universitätsmedizin Berlin and a board member of TauRx Therapeutics Ltd. He has more than 25 years of experience in animal-based genome manipulation. He is a consultant to the State of Berlin in Biotechnology, to the European Union in Molecular Medicine and to the pharmaceutical industry. He is an elected Member of the Berlin Scientific Society



(BWG) where he currently acts as a Vice President. In addition to these activities, he is co-founder of the Proteome Factory, a Berlin-based biotech company. Prof. Theuring graduated in biology from the Universities of Braunschweig and Göttingen. He subsequently earned a PhD from the University of Göttingen in 1986, and worked as a post-doctoral research fellow at the Max Planck Institute for Biophysical Chemistry. Prof. Theuring established transgenic technologies at the Max Planck Institute and later at the ICMB of Schering AG, Berlin. He received his Habilitation from the Free University of Berlin in Molecular Biology and Biochemistry in 1996, and after 8 years at Schering AG, was appointed in 1996 to a Professorship in Molecular Pharmacology at the Charité - Universitätsmedizin Berlin.



### **Markus Thill**

Markus Thill is Managing Director with RBVC and based in Frankfurt. He is responsible for RBVC's commercial fund and direct investment strategy, its commercial operations, as well as reporting into Bosch group management. For more than 20 years of his professional career, Markus has learned to quickly identify an organisation's competitive position and its critical operational requirements, is passionate about people management, setting clear goals and intense, hands-on follow-through. Prior to co-founding RBVC, he worked as Vice President of Bosch's global corporate strategy department both on strategies for existing as well as for new business areas of Bosch. Before joining Bosch, Markus was a senior manager in leading strategy consulting firms, heading and implementing projects on strategic and operational issues as well as M&A around the globe. His clients encompassed Global Fortune 500, mid-caps, and start-up companies as well as private equity and venture capital firms. Markus holds university degrees in mathematics and physics, including a doctorate ("summa cum laude") from Université de Paris (France), obtained with research work on statistical physics of disordered systems in Paris and AT&T Bell Labs (Murray Hill, NJ, USA). He is fluent in English, German, and French and has a good working knowledge of several other European languages.



### **Marc Van Aken**

Marc Van Aken has been working with startup teams for the last 7 years with SO Kwadraat, a not for profit organization that helps researcher start their company based on the results of their research. SO Kwadraat has worked with 180 starter teams which resulted in the creation of 67 companies to date. Marc holds a MSc in Electronic Engineering (University of Leuven, Belgium), a MA Management (University of Brussels, Belgium) and a MA Social Sciences (Open University, UK).



### **Gabriel Vanrenen**

Gabriel is a mobile technology expert who is passionate about creating consumer products that enable people to live healthier lives wherever they are. Prior to starting Skimble, Gabriel founded Flurry, a leading mobile analytics company, and was a software engineer at Wily Technology before its acquisition by CA. Gabriel graduated Summa Cum Laude from Dartmouth College with a B.A. in Computer Science and specialization in Computer Security, with research papers published in the First European PKI Workshop and the International Journal of Information Security. In his free time, Gabe enjoys advising digital technology startups and rock climbing around the world.

---



### **Johannes Velling**

Dr. Johannes Velling is Head of the sections "KfW" and "Seed and Start-Up Financing" in the Federal Ministry of Economics and Technology. Dr. Velling studied economics at the universities of Mannheim, Germany, and Eugene/Oregon, USA. During his dissertation between 1991 and 1995 he worked as a research fellow at the ZEW (Center of European Economic Research). In 1996 he changed to the German federal government. He held different positions at the Federal Ministry of Economics (BMWi) and the Federal Ministry of Education and Research (BMBF). Since the beginning of 2004 he has been responsible for the different federal programs for venture capital financing of young technological companies. In this function, he developed together with three industrial companies and the KfW Banking Group the "High-Tech Gründerfonds", where he serves as a deputy Head of the Supervisory Board since 2005. Besides the activities around the High-Tech Gründerfonds and the business angel issue, his section is responsible for the government program "EXIST", a program fostering entrepreneurship at universities and public research institutes and supporting spin-offs from science. His responsibilities also include the new "Investitionszuschuss Wagniskapital" (investment grant risk capital).

---



### **Thomas Wilckens**

Thomas Wilckens is an MD and a serial entrepreneur. His current focus is a novel start-up project with a focus on the convergence of \*omics technologies with real-world clinical data to enable *Precision Medicine*. Until 11/2012 served as Head of mHealth Solutions at deep innovation GmbH. Before joining deep innovation, he headed a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in biomedicine and nowadays mobile ICT he developed a novel concept for value creation in research intensive industries; i.e. Symbiotic Innovation. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in nano- and biotechnology; i.e. *Precision Medicine* will ultimately be supported by algorithms for diagnostics and therapeutic decision making and become available anywhere 24/7.

---



### **Yannick Wilden**

Yannick Wilden, is investment manager at Fraunhofer Venture, the department of the Fraunhofer Gesellschaft and in charge of the technology commercialization through spin-offs. In his role he manages a portfolio of hightech companies, supports and advises them with focus on technology exploitation, business development and financing. Before joining the Fraunhofer Venture team, he worked as analyst at a private investment management firm and for several years as senior account manager as well as project buyer at Valeo Group, one of the world's leading automotive suppliers. Through a successful international career in Germany, France and the US, Yannick leverages on nine years of industry experience and expertise in the development, production and financing of complex technical products. He holds a master degree in production engineering from the RWTH-Aachen and a MBA with distinction from the HULT International Business School in Boston.

---



### **Gabriel Yoran**

Gabriel Yoran is co-founder of consumer privacy software company Steganos (which he

started at the age of 17) and location-based social network, aka-aki. Gabriel is an expert in product design and consumer marketing with more than 15 years of professional experience. He is also a member of the European Union Social Networks Group. Gabriel is a mentor at the Founder Institute and Berlin Startup Academy and gives lectures on Entrepreneurship, Marketing, and Product Design. Products designed by Gabriel have earned numerous awards, including two Webby Awards, a Lead Award and numerous Best Buy and Product of the Year awards in magazines like PC World. Gabriel is a regular speaker at industry events such as the European Union's Future Internet Assembly, Webinale, World Usability Day, Web 2.0 Expo, Mobile 2.0 Summit, Startup Live. He studied Communication in Social and Economic Contexts and holds a Master of Arts from Berlin University of the Arts. He is now a Ph.D. candidate at the European Graduate School in Saas-Fee (Switzerland). He lives in Berlin, Germany.



### **Tamo Zwinge**

Tamo Zwinge, LL.M. is one of the founders and managing directors of the crowdfunding platform Companisto. Tamo Zwinge previously worked several years at CMS Hasche Sigle, a major international law firm, advising large corporations in the fields of corporate law and mergers and acquisitions. Already in 2001, he incorporated Partycard together with David Rhotert, also lawyer and co-founder of Companisto. They were managing directors of Partycard until their divestment in 2005. Tamo Zwinge studied law at the Freie Universität Berlin, completed his legal clerkship in Berlin and Pretoria, South Africa, and graduated with a Master of Laws degree in Commercial Law from the university of Auckland, New Zealand. Tamo Zwinge has published internationally on corporate governance topics.